Abstract

BackgroundRapid radiographic progression (RRP) is considered to be one of the factors in difficult to treat rheumatoid arthritis (RA). MRI bone marrow edema has been reported to be a risk...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
POS0481 BONE EDEMA IN MRI IS MORE ASSOCIATED WITH RAPID RADIOGRAPHIC PROGRESSION THAN CLINICALLY RELEVANT RADIOGRAPHIC PROGRESSION.
S Abe ... T Okubo
-
S Abe, et. al.S Abe ... T Okubo
30 May 2023
What Level of Inflammation Leads to Structural Damage in the Sacroiliac Joints? A Four-Year Magnetic Resonance Imaging Follow-Up Study of Low Back Pain Patients.
Bodil Arnbak ... Susanne J Pedersen
Arthritis & rheumatology (Hoboken, N.J.) | VOL. 71
Bodil Arnbak, et. al.Bodil Arnbak ... Susanne J Pedersen
09 Nov 2019
AB1335 BONE MARROW EDEMA SCORE IN HAND X-RAY FILM BY AI DEEP LEARNING ASSOCIATE WITH MRI BONE EDEMA IN RHEUMATOID ARTHRITIS.
K Mori ... T Okubo
-
K Mori, et. al.K Mori ... T Okubo
23 May 2022
SAT0100 Bone marrow OEDEMA is more associated with rapid radiographic progression than synovitis or bone erosion by using low field MRI in bio-naïve rheumatoid arthritis patients treated with adalimumab and methotrexate combination therapy
K Katayama ... T Matsuno
Annals of the Rheumatic Diseases | VOL. 71
K Katayama, et. al.K Katayama ... T Matsuno
01 Jun 2013
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers